Business
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. “We are truly delighted that Todd is joining Arcutis to take over the leadership of our commercial organization,” said Frank Watanabe, President and CEO of Arcutis. “Over many years, he has developed a deep understanding of what is needed to be commercially successful in dermatology, and his proven track record of successfully commercializing both topical and systemic therapies will be critical in light of our ongoing launch of ZORYVE cream in plaque psoriasis. In addition, we are excited about the impact he will have for topical roflumilast and the expected FDA approvals in other serious skin conditions including seborrheic dermatitis and atopic dermatitis.” “I am excited to join the Arcutis team and contribute to their efforts in developing and bringing meaningful innovations in immuno-dermatology to market while ensuring responsible pricing and broad accessibility to the individuals who need them,” said Mr. Edwards. “I look forward to working with the Commercial team to accelerate the momentum behind the launch of ZORYVE in plaque psoriasis, and preparing for potential future indications, while advancing Arcutis’ unique company culture focused on challenging the existing standard of care to address unmet needs in the treatment of immune-mediated skin diseases.” Mr. Edwards joins Arcutis from Incyte, where he was group vice president and business unit head for their immunology business, and led the successful launch and commercialization of their topical JAK inhibitor for atopic dermatitis. Previously, Mr. Edwards was head of US immunology and later head of global immunology operations and strategy for UCB, where he was instrumental in leading commerci...